Will Right-To-Try Morph into Right-To-Profit for Stem Cell Clinics?

FDA-RMAT

On one level a reasonable argument can be made for letting terminally ill patients have a right to try experimental as yet unproven therapies, but in the real world Right-To-Try laws have many downsides. On the whole, they are likely to be negative for patients as a group. ¬†Raising the stakes is a push for …

Will Right-To-Try Morph into Right-To-Profit for Stem Cell Clinics? Read More »